Product Description
Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Oncology Unspecified|Lung Cancer|Colorectal Cancer|Other
Phase 2: Oncology Unspecified|Enuresis|Overactive Bladder|Spinal Cord Injuries|Urinary Incontinence|Dyspepsia|Insomnia|Depressive Disorder, Major|Anesthesia Related|Other|Fibromyalgia
Phase 1: Healthy Volunteers|Phobia, Social|Oncology Unspecified|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00891761 | P3 |
Withdrawn |
Lung Cancer |
2010-07-01 |
|
NKV110721 | P3 |
Completed |
Colorectal Cancer |
2009-04-13 |
|
2007-005169-36 | P3 |
Completed |
Colorectal Cancer |
2009-04-07 |
|
NKT102783 | P1 |
Completed |
Kidney Diseases |
2008-08-22 |